Metabolic Dysfunction-Associated Steatohepatitis (MASH): Intersections with Type 2 Diabetes and Insulin Resistance

Metabolic dysfunction-associated steatohepatitis (MASH) represents a progressive form of metabolic liver disease characterized by hepatic inflammation, cellular injury, and fibrosis. Among the various metabolic disturbances implicated in its development, Type 2 Diabetes and insulin resistance stand out as key drivers of disease onset and progression. The complex crosstalk between hepatic lipid metabolism, insulin signaling, and systemic glucose homeostasis creates a multifaceted pathophysiological network that underpins both MASH and Type 2 Diabetes.

This Research Topic aims to bring together studies exploring the mechanistic and clinical relationships between MASH, insulin resistance, and Type 2 Diabetes. It welcomes contributions that deepen understanding of shared molecular pathways, metabolic and inflammatory mediators, and emerging therapeutic strategies targeting both hepatic and systemic metabolic dysfunction.

Potential areas of interest include but not limited to:

• Mechanistic insights linking hepatic lipid accumulation to insulin resistance and β - cell dysfunction.

• The role of adipokines, cytokines, and oxidative stress in mediating liver–pancreas crosstalk.

• Biomarkers and imaging tools for early detection of MASH in patients with Type 2 Diabetes.

• Pharmacological and lifestyle interventions addressing metabolic inflammation and insulin sensitivity.

• Integrated clinical management strategies for patients with coexisting MASH and Type 2 Diabetes.